Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00716898|
Recruitment Status : Completed
First Posted : July 16, 2008
Last Update Posted : April 15, 2016
|Condition or disease|
|Cancer Thrombosis Angina Pectoris|
|Study Type :||Observational|
|Actual Enrollment :||25 participants|
|Observational Model:||Case Control|
|Official Title:||Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients Compared to Patients With Unstable Angina Pectoris; The Possible Role of Heparanase|
|Study Start Date :||February 2009|
|Actual Primary Completion Date :||June 2011|
|Actual Study Completion Date :||June 2011|
A. Patients with pathologically or cytologically confirmed diagnosis of advanced solid malignancy.
B. Venous thromboembolism: Deep vein thrombosis (DVT) confirmed by Doppler ultrasound, or pulmonary embolism confirmed by lung ventilation perfusion scan, or computerized tomography.
C. Treatment with therapeutic dose of low molecular weight heparin. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. Serum creatinine level < 1.5 mg/dl. G. Informed consent
A. Patients with unstable angina pectoris/ atypical chest pain, with no evidence of acute myocardial infarction.
B. Treatment with therapeutic dose of low molecular weight heparin. C. No evidence of VTE. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. No history of malignancy. G. Serum creatinine level < 1.5 mg/dl. H. Informed consent
- Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients [ Time Frame: Interim analysis and at the end of the trial ]
- The role of heparanase on the Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients [ Time Frame: End of the study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00716898
|Shaare Zedek Medicla Center|
|Jerusalm, Israel, 91031|
|Principal Investigator:||Nicola j nasser, MD, PhD||Shaare Zedek MC|